Pliant Therapeutics presented updated Phase 1 data for its lead oncology asset, PLN‑101095, at the AACR 2026 Annual Meeting on April 18, 2026. The oral presentation by Dr. Timothy A. Yap of MD Anderson Cancer Center highlighted activity in 16 heavily pre‑treated, immune‑checkpoint‑inhibitor (ICI)‑refractory solid‑tumor patients across ten tumor types.
The data showed four confirmed responses—one complete response and three partial responses—in the heavily pre‑treated cohort. Responders experienced an average maximum tumor reduction of 89 % and a median time on treatment of 19 months, underscoring durable activity in a population with limited therapeutic options. Biomarker analysis revealed that all responders had 4‑ to 13‑fold increases in plasma interferon‑γ after a 14‑day monotherapy run‑in, with more than a 2‑fold increase maintained at Week 10. Elevated plasma PD‑L1 levels were also observed, supporting the proposed mechanism of TGF‑β inhibition and immune‑stimulation.
Safety data were consistent with the known profile of PLN‑101095. Rash was the most common treatment‑related adverse event, predominantly Grade 1 or 2, with a single Grade 3 event reported. Two patients discontinued treatment because of adverse events, and no other serious safety signals were identified.
Pliant’s financial position remains a key consideration for investors. The company reported a narrower net loss of $23.6 million for Q4 2025, compared with $49.7 million in the prior year, and an EPS of –$0.35 that beat consensus estimates of –$0.44. Cash on hand was $192.4 million as of December 31 2025, giving the company a runway that extends into the second half of 2028. The company’s cost‑control measures, including the discontinuation of the BEACON‑IPF trial and workforce restructuring, contributed to the improved profitability.
Dr. Yap emphasized the therapeutic potential of PLN‑101095: “PLN‑101095 is designed to inhibit the integrins before they can ever do that, which gives it significant potential to stimulate or reinvigorate the immune response to cancer. These clinical trial data, for the combination of PLN‑101095 and pembrolizumab, in patients with secondary immune checkpoint inhibitor resistance, show the potential to meet a high unmet therapeutic need.”
In addition to the Phase 1 data, Pliant has launched a Phase 1b indication‑expansion trial enrolling patients with non‑small cell lung cancer, tumors with high tumor mutational burden, or clear cell renal cell carcinoma. Interim data from this trial are expected in 2027, which will provide further insight into the drug’s activity across additional tumor types.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.